NASDAQ$TNDM

Tandem Diabetes Care Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported financial results for the first quarter of 2021 and updated sales guidance for the year ending December 31, 2021.

Tandem Diabetes Care announced a strong start to 2021 with record first-quarter sales, driven by increased pump shipments and international growth. The company updated its full-year sales guidance, reflecting confidence in continued positive momentum.

  • Worldwide pump shipments increased 46 percent year-over-year to 25,352 pumps.
  • Sales increased 44 percent year-over-year to $141.0 million.
  • Gross margin improved to 52 percent from 51 percent year-over-year.
  • Operating margin improved to negative 2 percent from negative 14 percent year-over-year.

Headline financials

Total Revenue

$141M

Previous: $97.9M+44.0%
EPS (adj)

-$0.08

Previous: -$0.25+68.0%
Worldwide Pump Shipments

25.4K

Previous: 17.4K+45.9%
Adjusted EBITDA

$13.2M

No prior period
Capital Expenditures

-$3.52M

Previous: -$6.77M+47.9%
Free Cash Flow

-$8.57M

Previous: -$21.6M+60.4%
Net Income

-$5.04M

Previous: -$14.9M+66.1%
Operating Income

-$3.24M

Previous: -$13.6M+76.2%
Gross Profit

$73.3M

Previous: $50.3M+45.8%
Cash & Equivalents

$121M

Previous: $160M-24.6%
Total Assets

$754M

Previous: $343M+119.7%
Stock-Based Comp

$12.9M

Previous: $15.9M-18.4%

Revenue & EPS history

Tandem Diabetes · Revenue · Quarterly

$141M

Q1 2021+44%vs Q1 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Tandem Diabetes · $80.7M total across 1 segment · Q3 2022

  • Pump Sales
    $80.7M

Forward guidance

The company updated its financial guidance for the year ending December 31, 2021.

Tailwinds

  • Sales are estimated to be in the range of $625 million to $640 million, representing 25% to 28% annual sales growth compared to 2020.
  • International sales are projected to be approximately $125 million to $130 million, indicating 50% to 56% annual sales growth compared to 2020.
  • Gross margin is estimated to be approximately 55%.
  • Adjusted EBITDA is estimated to be 14% to 15% of sales.
  • The company's prior sales guidance for 2021 was estimated to be in the range of $600 million to $615 million.

Headwinds

  • Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $80 million.
  • Approximately $65 million in non-cash, stock-based compensation expense.
  • Approximately $15 million of depreciation and amortization.
  • There is substantial uncertainty associated with predicting any future adjustments that we may make to our GAAP financial measures in calculating our non-GAAP financial measures.
  • The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.4%

Avg return

Earnings day

-2.2%

Avg return

5 days after

+3.5%

Avg return

30 days after

55%

27 / 49 earnings

Positive

+32.8%

Q4 2025

Best reaction

-63.6%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.6%-23.6%+5.0%
Q4 2025+32.8%+40.4%+34.0%
Q3 2025+22.0%+35.5%+56.9%
Q1 2025+18.6%+26.5%+17.6%
Q4 2024-35.2%-42.0%-42.6%
Q3 2024+0.6%-5.3%-9.1%
Q2 2024+12.7%+17.3%+17.6%
Q1 2024+23.5%+21.5%+41.5%
Q4 2023+6.1%+22.5%+28.4%
Q3 2023-12.1%-11.5%+22.5%
Q2 2023+2.8%-13.4%-14.3%
Q1 2023-2.9%-13.4%-35.9%
Q4 2022-2.1%-8.0%+8.0%
Q3 2022-34.3%-31.5%-23.7%
Q2 2022-14.0%-11.8%-34.3%
Q1 2022-16.4%-27.6%-33.8%
Q4 2021-0.3%+7.6%+7.6%
Q3 2021-4.9%-2.6%-4.3%
Q2 2021+4.7%+2.6%+8.8%
Q1 2021-5.6%-11.9%-5.8%
Q4 2020+3.5%+4.4%-10.0%
Q3 2020+1.5%-11.4%-17.9%
Q2 2020+1.8%+3.0%+10.1%
Q1 2020+7.6%+13.7%+11.5%
Q4 2019-11.4%-15.2%-34.7%
Q3 2019-6.5%-8.0%+2.2%
Q2 2019+2.9%-1.5%+14.2%
Q1 2019-5.8%+6.3%+9.2%
Q4 2018+27.9%+43.2%+31.8%
Q3 2018+6.3%-2.2%-2.1%
Q2 2018+7.7%+29.0%+59.9%
Q1 2018+7.9%+7.7%+96.4%
Q4 2017+23.1%+25.0%+57.0%
Q3 2017-3.4%-6.4%+2.7%
Q2 2017-17.3%-39.4%+8.7%
Q1 2017-11.8%-10.5%-22.4%
Q4 2016-19.1%-10.6%-51.1%
Q3 2016-63.6%-66.9%-63.2%
Q2 2016-13.9%-18.8%-8.4%
Q1 2016+7.1%
Q4 2015+11.9%
Q3 2015+20.6%
Q2 2015+8.9%
Q1 2015+1.7%
Q4 2014-3.1%
Q3 2014-11.0%
Q2 2014+11.4%
Q1 2014-11.7%
Q4 2013+4.0%
Q2 2013
Q1 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro